Answers are grounded in this paper and cite their sources.
Introduction Maxillomandibular complex (MMC) metastases are rare and present unfavorable prognoses. This systematic review aimed to identify epidemiological, clinical, imaging and histopathological characteristics associated to metastatic neoplasms, as well as the most employed treatments, follow-up times and outcomes. Methods Searches were carried out at the Web of Science, PubMed, Scopus, Science Direct and Periódicos Capes electronic databases encompassing the last 10 years (October 2013 to January 2024). Results Eighty-three articles were selected (159 patients) from 25 countries. Men were the most affected (59.73%), with a mean metastatic lesion diagnosis age of 56.5 years old. The most prevalent primary sites were the kidneys (18.2%). The mandible was the preferred metastasis region (50.3%). Regarding the first diagnosis, 31.5% of cases were initially detected at the primary lesion site and 28.9%, at the oral metastatic site. The most prevalent histopathological diagnoses were carcinomas (43.4%). Imaging tests reveal a higher rate of radiolucent/hypodense lesions (41.5%) predominantly in the mandible. Several treatments are routinely applied, but chemotherapy alone was the most frequent (21.4%). Average patient follow-up time was of about 13 months, and death was the most frequent outcome (52.2%). Conclusion Metastatic lesions affecting the MMC predominantly affect the mandible and often present a deceptively benign clinical appearance. The primary site of these lesions are most often organs that make up the urinary and respiratory systems. Despite various available treatments, these lesions carry a poor prognosis, with death comprising the most common outcome.
No takes yet. Share an insight, caveat, or question.
Vital et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: